Sympathetic ophthalmia: epidemiology and cohort-based assessment of clinical outcomes.

Epidemiology Inflammation Trauma

Journal

The British journal of ophthalmology
ISSN: 1468-2079
Titre abrégé: Br J Ophthalmol
Pays: England
ID NLM: 0421041

Informations de publication

Date de publication:
02 Oct 2024
Historique:
received: 27 01 2024
accepted: 18 08 2024
medline: 3 10 2024
pubmed: 3 10 2024
entrez: 2 10 2024
Statut: aheadofprint

Résumé

The purpose of this study was to report the incidence, time after inciting event, aetiology and risk after specific intraocular procedures and the visual outcomes associated with sympathetic ophthalmia (SO) occurrence. This study reports data from multiple retrospective cohorts: retrospective population-based data were extracted from the TRICARE service network (between 2017 and 2021) and retrospective case-based data from the Ocular Autoimmune Systemic Inflammatory Infectious Study (OASIS) database (cohorts from the UK, South India and North India). There were 159 patients with SO identified. The length of time from sensitising event to SO occurrence was a median of 151 days (range: 6-9100 days).In the TRICARE database, 2 patients developed SO after open globe trauma and primary repair (of 615 eyes, rate 0.33%; 95% CI 1.26% to 1.30%). None developed SO after vitrectomy (total of 23 903 events; 95% CI 0% to 0.012%). The combined North Indian and UK cohorts reported 78.6% (81 patients) after trauma, 18.45% (19 patients) after elective surgery.Visual outcomes were reported in the OASIS database for 98.01% of patients (155 of 157 patients). The median presenting and final best corrected visual acuity (BCVA) for the inciting eye were no perception of light, the median presenting and final BCVA for the sympathising eye were 0.65 and 0.3 logMAR, respectively. This study identified 159 cases of SO. With poor visual outcomes in the inciting eye, early diagnosis and management are crucial for optimising visual outcomes in the sympathising eye.

Sections du résumé

BACKGROUND BACKGROUND
The purpose of this study was to report the incidence, time after inciting event, aetiology and risk after specific intraocular procedures and the visual outcomes associated with sympathetic ophthalmia (SO) occurrence.
METHODS METHODS
This study reports data from multiple retrospective cohorts: retrospective population-based data were extracted from the TRICARE service network (between 2017 and 2021) and retrospective case-based data from the Ocular Autoimmune Systemic Inflammatory Infectious Study (OASIS) database (cohorts from the UK, South India and North India).
RESULTS RESULTS
There were 159 patients with SO identified. The length of time from sensitising event to SO occurrence was a median of 151 days (range: 6-9100 days).In the TRICARE database, 2 patients developed SO after open globe trauma and primary repair (of 615 eyes, rate 0.33%; 95% CI 1.26% to 1.30%). None developed SO after vitrectomy (total of 23 903 events; 95% CI 0% to 0.012%). The combined North Indian and UK cohorts reported 78.6% (81 patients) after trauma, 18.45% (19 patients) after elective surgery.Visual outcomes were reported in the OASIS database for 98.01% of patients (155 of 157 patients). The median presenting and final best corrected visual acuity (BCVA) for the inciting eye were no perception of light, the median presenting and final BCVA for the sympathising eye were 0.65 and 0.3 logMAR, respectively.
CONCLUSION CONCLUSIONS
This study identified 159 cases of SO. With poor visual outcomes in the inciting eye, early diagnosis and management are crucial for optimising visual outcomes in the sympathising eye.

Identifiants

pubmed: 39357991
pii: bjo-2024-325267
doi: 10.1136/bjo-2024-325267
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Weidong Gu (W)

Defense Health Agency, Falls Church, Virginia, USA.

David Eliason (D)

Defense Health Agency, Falls Church, Virginia, USA.

William Rojas-Carabali (W)

Neurosciences Research Group (NEUROS), NeuroVitae Center for Neuroscience, Universidad Del Rosario, Escuela de Medicina y Ciencias de la Salud, Bogota, Colombia.

Bernett Lee (B)

Lee Kong Chian School of Medicine, Singapore.

Padmamalini Mahendradas (P)

Uveitis and Ocular Immunology, Narayana Nethralaya, Bangalore, Karnataka, India.

Jyotrimay Biswas (J)

Uvea Clinic, Vision Research Foundation, Chennai, Tamil Nadu, India.

Parthopratim Dutta Majumder (PD)

Uvea Clinic, Vision Research Foundation, Chennai, Tamil Nadu, India.

Manisha Agarwal (M)

Vitreo-retina, Dr. Shroff's Charity Eye Hospital, New Delhi, New Delhi, India.

Carlos Pavesio (C)

Moorfields Eye Hospital NHS Foundation Trust, London, UK.
UCL Institute of Ophthalmology, London, UK.

Vishali Gupta (V)

Department of Ophthalmology, Postgraduate Institute of Medical Education and Research, Chandigarh, Punjab and Haryana, India.

Rupesh Agrawal (R)

Department of Ophthalmology, National Healthcare Group Eye Institute, Singapore.

Richard James Blanch (RJ)

Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK R.J.Blanch@bham.ac.uk.
Academic Department of Military Surgery and Trauma, Royal Centre for Defence Medicine, Birmingham, UK.

Classifications MeSH